CVBT Will Present at the Prudential West Coast Biotech Investor Day.LAS VEGAS -- CardioVascular BioTherapeutics, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CVBT) announced today that Mr. Daniel C. Montano, CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. and Dr. Jack Jacobs, COO and Chief Scientific Officer of CardioVascular BioTherapeutics, Inc. (CVBT), have been invited to present CVBT's medical advances at the Prudential Equity Group's WEST COAST BIOTECH INVESTOR DAY on June 19, 2006. The event is being held at The Omni Hotel in San Francisco, California “San Francisco” redirects here. For other uses, see San Francisco (disambiguation). The City and County of San Francisco (EN IPA: [sænfrənˈsɪskoʊ] . Mr. Montano commented, "I am very pleased with this opportunity to present our company at this prestigious event." CVBT is a biopharmaceutical company developing drug candidates with Cardio Vascu-Grow(TM) as the active ingredient for a number of diseases characterized by inadequate blood flow to a tissue or organ. Currently, the company is conducting two FDA-authorized clinical trials: one in the area of coronary artery disease coronary artery disease, condition that results when the coronary arteries are narrowed or occluded, most commonly by atherosclerotic deposits of fibrous and fatty tissue. in no-option heart patients, and one in the area of impaired wound healing seen in diabetics. Additionally, the company has completed pre-clinical studies in animal models of peripheral vascular disease Peripheral Vascular Disease Definition Peripheral vascular disease is a narrowing of blood vessels that restricts blood flow. It mostly occurs in the legs, but is sometimes seen in the arms. of the legs and stroke recovery. Clinical trials in these two indications are planned to begin later this year in the U.S.A. A foreign clinical trial relating to chronic back pain believed to be caused by impaired or blocked arteries has also been initiated. Cardio Vascu-Grow(TM) is a trademark of CardioVascular BioTherapeutics, Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion